CA2967720C - Tri-segmented arenaviruses as vaccine vectors - Google Patents

Tri-segmented arenaviruses as vaccine vectors Download PDF

Info

Publication number
CA2967720C
CA2967720C CA2967720A CA2967720A CA2967720C CA 2967720 C CA2967720 C CA 2967720C CA 2967720 A CA2967720 A CA 2967720A CA 2967720 A CA2967720 A CA 2967720A CA 2967720 C CA2967720 C CA 2967720C
Authority
CA
Canada
Prior art keywords
arenavirus
segment
orf
tri
segmented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2967720A
Other languages
English (en)
French (fr)
Other versions
CA2967720A1 (en
Inventor
Daniel David PINSCHEWER
Doron Merkler
Sandra Margarete KALLERT
Mario KREUTZFELDT
Stephanie Gabrielle DARBRE ABDELRAHMAN
Nicolas Jean PAGE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Geneve
Original Assignee
Universite de Geneve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54545130&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2967720(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Universite de Geneve filed Critical Universite de Geneve
Publication of CA2967720A1 publication Critical patent/CA2967720A1/en
Application granted granted Critical
Publication of CA2967720C publication Critical patent/CA2967720C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10061—Methods of inactivation or attenuation
    • C12N2760/10062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/80—Vectors comprising a special translation-regulating system from vertebrates
    • C12N2840/85—Vectors comprising a special translation-regulating system from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2967720A 2014-11-13 2015-11-12 Tri-segmented arenaviruses as vaccine vectors Active CA2967720C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462079493P 2014-11-13 2014-11-13
US62/079,493 2014-11-13
PCT/EP2015/076458 WO2016075250A1 (en) 2014-11-13 2015-11-12 Tri-segmented arenaviruses as vaccine vectors

Publications (2)

Publication Number Publication Date
CA2967720A1 CA2967720A1 (en) 2016-05-19
CA2967720C true CA2967720C (en) 2024-01-02

Family

ID=54545130

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2967720A Active CA2967720C (en) 2014-11-13 2015-11-12 Tri-segmented arenaviruses as vaccine vectors

Country Status (17)

Country Link
US (3) US10722564B2 (OSRAM)
EP (2) EP3778903A1 (OSRAM)
JP (4) JP6805139B2 (OSRAM)
CN (1) CN107223130A (OSRAM)
AU (3) AU2015345080B2 (OSRAM)
CA (1) CA2967720C (OSRAM)
CY (1) CY1123339T1 (OSRAM)
DK (1) DK3218504T3 (OSRAM)
ES (1) ES2811093T3 (OSRAM)
HR (1) HRP20201684T1 (OSRAM)
HU (1) HUE051390T2 (OSRAM)
LT (1) LT3218504T (OSRAM)
PL (1) PL3218504T3 (OSRAM)
PT (1) PT3218504T (OSRAM)
RS (1) RS60937B1 (OSRAM)
SI (1) SI3218504T1 (OSRAM)
WO (1) WO2016075250A1 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2604695T (lt) 2007-12-27 2022-12-12 Universität Zürich Replikacijos defektų turintys arenaviruso vektoriai
JP6818551B2 (ja) * 2013-12-03 2021-01-20 ホオキパ バイオテック ジーエムビーエイチ Ｃｍｖワクチン
CA2967720C (en) 2014-11-13 2024-01-02 Universite De Geneve Tri-segmented arenaviruses as vaccine vectors
AU2016274655B2 (en) * 2015-06-10 2021-06-17 Hookipa Biotech Gmbh HPV vaccines
WO2018045029A1 (en) * 2016-09-02 2018-03-08 The United States Of America, As Represented By The Secretary Of The Army Pan south american arenavirus live attenuated vaccine
SG11201803474UA (en) * 2015-11-04 2018-05-30 Hookipa Biotech Ag Vaccines against hepatitis b virus
CN108697775B (zh) * 2015-11-12 2023-05-09 霍欧奇帕生物科技有限公司 作为癌症疫苗的沙粒病毒颗粒
CA3039356A1 (en) * 2016-11-04 2018-05-11 Hookipa Biotech Gmbh Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
WO2018185307A1 (en) 2017-04-07 2018-10-11 Hookipa Biotech Ag Arenavirus particles to treat solid tumors
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
CN108611310A (zh) * 2018-04-28 2018-10-02 中国药科大学 一种重组Hsp65与STEAP1186-193融合蛋白的基因工程菌的构建
CN108977434A (zh) * 2018-07-03 2018-12-11 张罗 鼻腔脱落细胞rna的提取方法
EP3986455A1 (en) * 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Company Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof
CN120775062A (zh) 2019-07-16 2025-10-14 吉利德科学公司 Hiv疫苗及其制备和使用方法
MX2022003658A (es) 2019-09-30 2022-04-25 Gilead Sciences Inc Vacunas contra el virus de la hepatitis b (vhb) y metodos para tratar el vhb.
AU2020377504A1 (en) 2019-11-07 2022-06-02 Universität Basel Arenaviruses as vectors
JP2023527083A (ja) 2020-05-29 2023-06-26 ホオキパ バイオテック ジーエムビーエイチ アレナウイルスベクターを使用するがんの治療方法
WO2022155258A1 (en) 2021-01-14 2022-07-21 Gilead Sciences, Inc. Hiv vaccines and methods of using
WO2022159664A1 (en) * 2021-01-22 2022-07-28 Chan Zuckerberg Biohub, Inc. Engineered multi-segmented rna viruses for large-scale combinatorial genetic screening
AU2022244100A1 (en) 2021-03-23 2023-10-19 Hookipa Biotech Gmbh Arenaviruses used in treatments of prostate cancer
WO2022238546A1 (en) 2021-05-13 2022-11-17 Hookipa Biotech Gmbh Arenaviruses as vectors
AU2022381821A1 (en) 2021-11-08 2024-05-23 Hookipa Biotech Gmbh Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies
CN114231562A (zh) * 2021-12-15 2022-03-25 中国科学院武汉病毒研究所 一种表达荧光素酶基因的淋巴脉络丛脑膜炎病毒及其构建方法和应用
EP4475879A1 (en) 2022-02-08 2024-12-18 Hookipa Biotech GmbH Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
EP4554628A1 (en) 2022-07-12 2025-05-21 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
WO2025056782A1 (en) 2023-09-15 2025-03-20 Hookipa Biotech Gmbh Arenavirus formulations, methods and uses thereof
WO2025191169A1 (en) 2024-03-15 2025-09-18 Hookipa Biotech Gmbh Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US8158413B2 (en) * 2005-10-17 2012-04-17 Institut Pasteur Lentiviral vector-based vaccine
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2007765B1 (en) 2006-03-23 2012-06-27 Novartis AG Immunopotentiating compounds
LT2604695T (lt) 2007-12-27 2022-12-12 Universität Zürich Replikacijos defektų turintys arenaviruso vektoriai
GB201001726D0 (en) * 2010-02-03 2010-03-24 Univ St Andrews Bunyavirus vaccine
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
JP6219849B2 (ja) 2012-01-24 2017-10-25 サンフォード ヘルス 発癌性ウイルスポリペプチド陽性腫瘍治療用ポリヌクレオチド
WO2014140301A1 (en) 2013-03-15 2014-09-18 Université De Genève Anti-mycobacterial vaccines
GB201305361D0 (en) 2013-03-25 2013-05-08 Univ Edinburgh Enhanced expression
JP6818551B2 (ja) 2013-12-03 2021-01-20 ホオキパ バイオテック ジーエムビーエイチ Ｃｍｖワクチン
WO2015183895A1 (en) 2014-05-27 2015-12-03 University Of Rochester Novel arenavirus vaccine
US9943585B2 (en) 2014-07-30 2018-04-17 University Of Rochester Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV)
ES2746150T3 (es) * 2014-09-22 2020-03-04 Univ Minnesota Sistema de genética inversa para el virus Pichindé y métodos de uso
GB201419572D0 (en) 2014-11-03 2014-12-17 Pirbright Inst The Virus
CA2967720C (en) 2014-11-13 2024-01-02 Universite De Geneve Tri-segmented arenaviruses as vaccine vectors
DE102015207036A1 (de) 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
AU2016274655B2 (en) 2015-06-10 2021-06-17 Hookipa Biotech Gmbh HPV vaccines
ES3021881T3 (en) 2015-10-23 2025-05-27 Pasteur Institut Recombinant mopeia virus and vaccine platform
SG11201803474UA (en) 2015-11-04 2018-05-30 Hookipa Biotech Ag Vaccines against hepatitis b virus
CN108697775B (zh) 2015-11-12 2023-05-09 霍欧奇帕生物科技有限公司 作为癌症疫苗的沙粒病毒颗粒
CA3023599A1 (en) 2016-05-18 2017-11-23 Hookipa Biotech Gmbh Tri-segmented pichinde viruses as vaccine vectors
CA3039356A1 (en) 2016-11-04 2018-05-11 Hookipa Biotech Gmbh Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
WO2018185307A1 (en) 2017-04-07 2018-10-11 Hookipa Biotech Ag Arenavirus particles to treat solid tumors

Also Published As

Publication number Publication date
SI3218504T1 (sl) 2020-11-30
US20170319673A1 (en) 2017-11-09
CY1123339T1 (el) 2021-12-31
RS60937B1 (sr) 2020-11-30
JP2023036933A (ja) 2023-03-14
JP2017535267A (ja) 2017-11-30
AU2022200061A1 (en) 2022-02-03
WO2016075250A1 (en) 2016-05-19
US20240082376A1 (en) 2024-03-14
HK1244034A1 (en) 2018-07-27
ES2811093T3 (es) 2021-03-10
US20210145950A1 (en) 2021-05-20
AU2015345080B2 (en) 2022-01-27
CN107223130A (zh) 2017-09-29
JP6805139B2 (ja) 2020-12-23
PL3218504T3 (pl) 2021-02-08
LT3218504T (lt) 2020-09-10
JP2025170342A (ja) 2025-11-18
EP3778903A1 (en) 2021-02-17
AU2015345080A1 (en) 2017-06-01
CA2967720A1 (en) 2016-05-19
AU2024259760A1 (en) 2024-11-28
US10722564B2 (en) 2020-07-28
HUE051390T2 (hu) 2021-03-01
EP3218504A1 (en) 2017-09-20
EP3218504B1 (en) 2020-07-22
HRP20201684T1 (hr) 2020-12-25
PT3218504T (pt) 2020-09-24
DK3218504T3 (da) 2020-10-19
JP2021045154A (ja) 2021-03-25

Similar Documents

Publication Publication Date Title
US20240082376A1 (en) Tri-segmented arenaviruses as vaccine vectors
US20220289797A1 (en) Tri-segmented pichinde viruses as vaccine vectors
HK40036451A (en) Tri-segmented arenaviruses as vaccine vectors
HK1244034B (en) Tri-segmented arenaviruses as vaccine vectors
HK40004707A (zh) 作为疫苗载体的三区段pichinde病毒
HK40004707B (zh) 作为疫苗载体的三区段pichinde病毒
EA046869B1 (ru) Вирусы пичинде с трехсегментным геномом в качестве векторных вакцин

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201112

EEER Examination request

Effective date: 20201112

EEER Examination request

Effective date: 20201112

EEER Examination request

Effective date: 20201112

EEER Examination request

Effective date: 20201112

EEER Examination request

Effective date: 20201112

EEER Examination request

Effective date: 20201112

EEER Examination request

Effective date: 20201112

EEER Examination request

Effective date: 20201112

EEER Examination request

Effective date: 20201112

EEER Examination request

Effective date: 20201112